Aileen L.
About Aileen L.
Aileen L. is a Manager of Project Management with expertise in the formulation development of monoclonal antibodies and antibody-drug conjugates. She holds a Master of Science in Management of Drug Development from the University of Southern California and has extensive experience in cGMP and CMC activities within biologics development.
Work at Kite Pharma
Currently, Aileen L. serves as the Manager of Project Management at Kite Pharma, a position she has held since 2020. In this role, she oversees various project management activities, ensuring the successful development of biologics. Prior to this, she worked as a Senior Project Management Associate at Kite Pharma from 2019 to 2020. Her experience at Kite Pharma also includes a tenure as a CMC Project Coordinator from 2018 to 2019, where she contributed to the coordination of Chemistry, Manufacturing, and Controls (CMC) activities.
Education and Expertise
Aileen L. holds a Master of Science in Management of Drug Development from the University of Southern California, which she completed from 2015 to 2016. She also earned a Bachelor of Science in Biochemistry from the same institution, studying from 2006 to 2009. Her educational background supports her expertise in the formulation development of monoclonal antibodies and antibody-drug conjugates, as well as in pre-formulation and formulation development of parental protein therapeutics.
Background
Aileen L. has a solid foundation in the pharmaceutical industry, having previously worked at Astellas Pharma as a Senior Associate from 2011 to 2017. Her experience spans over a decade, during which she has developed a strong skill set in project management and CMC activities within preclinical and clinical biologics development. She has worked extensively with both cysteine-linked and site-specific antibody-drug conjugate platforms.
Achievements
Throughout her career, Aileen L. has utilized electronic notebooks with IDBS and Biobook applications for effective project management. Her work has involved significant contributions to the development of biologics, particularly in the areas of formulation and CMC activities. Her expertise in both liquid and lyophilized forms of therapeutics has positioned her as a knowledgeable professional in the field.